All Stories

  1. Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)—a white paper

    Article • Supportive Care in Cancer, January 2024, Springer Science + Business Media

    Dr. Paola Alberti

  2. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy

    Article • Supportive Care in Cancer, December 2023, Springer Science + Business Media

    Dr. Paola Alberti

  3. Effect of age on metabolomic changes in a model of paclitaxel‐induced peripheral neurotoxicity

    Article • Journal of the Peripheral Nervous System, December 2023, Wiley

    Dr. Paola Alberti

  4. Morphofunctional characterisation of axonal damage in different rat models of chemotherapy‐induced peripheral neurotoxicity: the role of nerve excitability testing

    Article • Journal of the Peripheral Nervous System, November 2023, Wiley

    Dr. Paola Alberti

  5. Gait analysis in chemotherapy-induced peripheral neurotoxicity rodent models

    Article • Brain Research Bulletin, October 2023, Elsevier

    Dr. Paola Alberti

  6. PNS Abstracts 2023

    Article • Journal of the Peripheral Nervous System, October 2023, Wiley

    Dr. Paola Alberti

  7. Toxic medications in Charcot–Marie–Tooth patients: A systematic review

    Article • Journal of the Peripheral Nervous System, June 2023, Wiley

    Dr. Paola Alberti

  8. Abstracts

    Article • Journal of the Peripheral Nervous System, May 2023, Wiley

    Dr. Paola Alberti

  9. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)

    Article • Supportive Care in Cancer, April 2023, Springer Science + Business Media

    Dr. Paola Alberti

  10. Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence

    Article • Journal of Neurology Neurosurgery & Psychiatry, April 2023, BMJ

    Dr. Paola Alberti

  11. Inhibition of NHE1 transport activity and gene transcription in DRG neurons in oxaliplatin-induced painful peripheral neurotoxicity

    Article • Scientific Reports, March 2023, Springer Science + Business Media

    Dr. Paola Alberti

  12. Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity

    Article • Toxics, January 2023, MDPI AG

    Dr. Paola Alberti

  13. Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy

    Article • International Journal of Molecular Sciences, January 2023, MDPI AG

    Dr. Paola Alberti

  14. Neurological Complications of Conventional and Novel Anticancer Treatments

    Article • Cancers, December 2022, MDPI AG

    Dr. Paola Alberti

  15. Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage?

    Article • International Journal of Molecular Sciences, September 2022, MDPI AG

    Dr. Paola Alberti

  16. Neurons: The Interplay between Cytoskeleton, Ion Channels/Transporters and Mitochondria

    Article • Cells, August 2022, MDPI AG

    Dr. Paola Alberti

  17. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients

    Article • Journal of the Peripheral Nervous System, April 2022, Wiley

    Dr. Paola Alberti

  18. Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain

    Article • Frontiers in Pharmacology, January 2022, Frontiers

    Dr. Paola Alberti

  19. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity

    Article • January 2022, Springer Science + Business Media

    Dr. Paola Alberti

  20. Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion

    Article • Expert Review of Neurotherapeutics, December 2021, Taylor & Francis

    Dr. Paola Alberti

  21. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations

    Article • Critical Reviews in Oncology/Hematology, December 2021, Elsevier

    Dr. Paola Alberti, Prof Stefano Tamburin

  22. Proceedings of the 31st National Conference of the Italian Group for the Study of Neuromorphology “Gruppo Italiano per lo Studio della Neuromorfologia” G.I.S.N., Milan, November 26-27, 2021

    Article • European Journal of Histochemistry, November 2021, PAGEPress Publications

    Dr. Paola Alberti

  23. Neurology of COVID-19

    Article • November 2021, Milano University Press

    Dr. Paola Alberti

  24. Translating morphology from bench side to bed side via neurophysiology: 8-min protocol for peripheral neuropathy research

    Article • Journal of Neuroscience Methods, November 2021, Elsevier

    Dr. Paola Alberti

  25. Correction for Pero et al., Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy

    Article • Proceedings of the National Academy of Sciences, November 2021, Proceedings of the National Academy of Sciences

    Dr. Paola Alberti

  26. Abstracts of the Eleventh Annual Meeting of the Associazione Italiana Sistema Nervoso Periferico (ASNP)

    Article • Journal of the Peripheral Nervous System, November 2021, Wiley

    Dr. Paola Alberti

  27. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity

    Article • Neurology, June 2021, Wolters Kluwer Health

    Dr. Paola Alberti

  28. Chemotherapy induced peripheral neurotoxicity: Six essential articles for effective future research

    Article • Experimental Neurology, March 2021, Elsevier

    Dr. Paola Alberti

  29. Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function

    Article • Brain Sciences, January 2021, MDPI AG

    Dr. Paola Alberti

  30. Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity

    Article • International Journal of Molecular Sciences, January 2021, MDPI AG

    Dr. Paola Alberti

  31. Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy

    Article • Proceedings of the National Academy of Sciences, January 2021, Proceedings of the National Academy of Sciences

    Dr. Paola Alberti, Francesca Bartolini

  32. Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Current Clinical Data and Future Directions

    Article • January 2021, Springer Science + Business Media

    Dr. Paola Alberti

  33. Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review

    Article • Cancer Treatment and Research Communications, January 2021, Elsevier

    Dr. Paola Alberti

  34. A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy

    Article • Expert Opinion on Drug Metabolism & Toxicology, October 2020, Taylor & Francis

    Dr. Paola Alberti

  35. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice

    Article • Journal of Clinical Investigation, June 2020, American Society for Clinical Investigation

    Dr. Paola Alberti

  36. Role of neurophysiology in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

    Article • Clinical Neurophysiology, May 2020, Elsevier

    Dr. Paola Alberti

  37. Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review

    Article • The Lancet Haematology, May 2020, Elsevier

    Dr. Paola Alberti

  38. Guillain-Barré syndrome related to COVID-19 infection

    Article • Neurology Neuroimmunology & Neuroinflammation, April 2020, Wolters Kluwer Health

    Dr. Paola Alberti

  39. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity

    Article • Archives of Toxicology, April 2020, Springer Science + Business Media

    Dr. Paola Alberti

  40. Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity

    Article • The FASEB Journal, April 2020, Wiley

    Dr. Paola Alberti

  41. Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy

    Article • Experimental Neurology, March 2020, Elsevier

    Dr. Paola Alberti

  42. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.

    Article • Neuropharmacology, December 2019, Elsevier

    Dr. Paola Alberti

  43. Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

    Article • Journal of the Peripheral Nervous System, October 2019, Wiley

    Dr. Paola Alberti

  44. Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue

    Article • Journal of the Peripheral Nervous System, October 2019, Wiley

    Dr. Paola Alberti, Prof Stefano Tamburin

  45. Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

    Article • Journal of the Peripheral Nervous System, October 2019, Wiley

    Dr. Paola Alberti

  46. Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment

    Article • Journal of the Peripheral Nervous System, October 2019, Wiley

    Dr. Paola Alberti, Prof Stefano Tamburin

  47. Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

    Article • Journal of the Peripheral Nervous System, October 2019, Wiley

    Dr. Paola Alberti

  48. Liability Of The Voltage‐Gated Potassium Channel KCNN3 Repeat Polymorphism To Acute Oxaliplatin‐Induced Peripheral Neurotoxicity

    Article • Journal of the Peripheral Nervous System, September 2019, Wiley

    Dr. Paola Alberti

  49. Pathogenic Role of Delta 2 Tubulin in Bortezomib Induced Peripheral Neuropathy

    Article • August 2019, Cold Spring Harbor Laboratory Press

    Dr. Paola Alberti

  50. Toxic neuropathies

    Article • Current Opinion in Neurology, July 2019, Wolters Kluwer Health

    Dr. Paola Alberti

  51. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 2019, BMJ

    Dr. Paola Alberti, Andreas Argyriou, Prof Stefano Tamburin

  52. Introduction to the Italian section for young neurologists

    Article • Neurological Sciences, June 2019, Springer Science + Business Media

    Dr. Paola Alberti

  53. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence

    Article • Expert Opinion on Drug Metabolism & Toxicology, May 2019, Taylor & Francis

    Dr. Paola Alberti

  54. Patients’ and physicians’ interpretation of chemotherapy-induced peripheral neurotoxicity

    Article • Journal of the Peripheral Nervous System, January 2019, Wiley

    Dr. Paola Alberti

  55. Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models

    Article • European Journal of Pharmacology, September 2018, Elsevier

    Dr. Paola Alberti

  56. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats

    Article • Journal of Neuroinflammation, August 2018, Springer Science + Business Media

    Dr. Paola Alberti

  57. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire

    Article • Health and Quality of Life Outcomes, June 2018, Springer Science + Business Media

    Dr. Paola Alberti

  58. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy

    Article • Experimental Neurology, June 2018, Elsevier

    Dr. Paola Alberti

  59. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Stand...

    Article • Cancer Nursing, April 2018, Wolters Kluwer Health

    Dr. Paola Alberti

  60. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve

    Article • Supportive Care in Cancer, March 2018, Springer Science + Business Media

    Dr. Paola Alberti

  61. Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes

    Article • Neurotoxicity Research, January 2018, Springer Science + Business Media

    Prof. Carlo Santini, Dr. Paola Alberti

  62. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity

    Article • Journal of Clinical Investigation, January 2018, American Society for Clinical Investigation

    Dr. Paola Alberti

  63. Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery

    Article • Cancer Research, November 2017, American Association for Cancer Research (AACR)

    Dr. Paola Alberti

  64. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial

    Article • Neurotherapeutics, September 2017, Springer Science + Business Media

    Dr. Paola Alberti

  65. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure

    Article • Oncology Nursing Forum, September 2017, Oncology Nursing Society (ONS)

    Dr. Paola Alberti, Dr Robert Knoerl

  66. Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study

    Article • International Archives of Occupational and Environmental Health, July 2017, Springer Science + Business Media

    Dr. Paola Alberti

  67. Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study

    Article • International Archives of Occupational and Environmental Health, June 2017, Springer Science + Business Media

    Dr. Paola Alberti

  68. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

    Article • Quality of Life Research, June 2017, Springer Science + Business Media

    Dr. Paola Alberti

  69. Abstracts

    Article • Journal of the Peripheral Nervous System, April 2017, Wiley

    Dr. Paola Alberti

  70. Chemotherapy-induced peripheral neurotoxicity – outcome measures: the issue

    Article • Expert Opinion on Drug Metabolism & Toxicology, November 2016, Taylor & Francis

    Dr. Paola Alberti

  71. Severe, reversible nelarabine-induced neuropathy and myelopathy

    Article • Journal of the Peripheral Nervous System, September 2016, Wiley

    Dr. Paola Alberti

  72. Abstracts

    Article • Journal of the Peripheral Nervous System, April 2016, Wiley

    Dr. Paola Alberti

  73. Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke

    Article • Journal of Neuroinflammation, January 2016, Springer Science + Business Media

    Dr. Paola Alberti

  74. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis

    Article • Journal of the Peripheral Nervous System, March 2015, Wiley

    Dr. Paola Alberti

  75. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: An Underdiagnosed Clinical Entity?

    Article • American Society of Clinical Oncology Educational Book, January 2015, American Society of Clinical Oncology (ASCO)

    Dr. Paola Alberti

  76. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study

    Article • Journal of the Peripheral Nervous System, December 2014, Wiley

    Dr. Paola Alberti

  77. Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study

    Article • Journal of the Peripheral Nervous System, June 2014, Wiley

    Dr. Paola Alberti

  78. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy

    Article • January 2014, Springer Science + Business Media

    Dr. Paola Alberti

  79. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

    Article • Annals of Oncology, November 2013, Oxford University Press (OUP)

    Dr. Paola Alberti

  80. Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue

    Article • Pain Management, November 2013, Future Medicine

    Dr. Paola Alberti

  81. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

    Article • European Journal of Cancer, September 2013, Elsevier

    Dr. Paola Alberti

  82. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study

    Article • Cancer, July 2013, Wiley

    Dr. Paola Alberti

  83. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 2013, BMJ

    Dr. Paola Alberti

  84. Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective

    Article • Annals of Oncology, March 2013, Oxford University Press (OUP)

    Dr. Paola Alberti

  85. Advanced age and liability to oxaliplatin-induced peripheral neuropathy:post hocanalysis of a prospective study

    Article • European Journal of Neurology, December 2012, Wiley

    Dr. Paola Alberti

  86. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer

    Article • Cancer Chemotherapy and Pharmacology, October 2012, Springer Science + Business Media

    Dr. Paola Alberti

  87. Neurophysiological examination of dorsal sural nerve

    Article • Muscle & Nerve, October 2012, Wiley

    Dr. Paola Alberti

  88. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

    Article • Annals of Oncology, August 2012, Oxford University Press (OUP)

    Dr. Paola Alberti

  89. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

    Article • Annals of Oncology, August 2012, Oxford University Press (OUP)

    Dr. Paola Alberti

  90. Clinical pattern and associations of oxaliplatin acute neurotoxicity

    Article • Cancer, July 2012, Wiley

    Dr. Paola Alberti

  91. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

    Article • The Lancet Oncology, November 2011, Elsevier

    Dr. Paola Alberti

  92. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale

    Article • Journal of the Peripheral Nervous System, September 2011, Wiley

    Dr. Paola Alberti

  93. Chemotherapy-Induced Neuropathy

    Article • Current Treatment Options in Neurology, December 2010, Springer Science + Business Media

    Dr. Paola Alberti

  94. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools

    Article • European Journal of Cancer, February 2010, Elsevier

    Dr. Paola Alberti